Boxer Capital LLC maintained its position in shares of Strongbridge Biopharma PLC (NASDAQ:SBBP) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 940,000 shares of the biotechnology company’s stock at the end of the first quarter. Strongbridge Biopharma PLC comprises approximately 1.0% of Boxer Capital LLC’s portfolio, making the stock its 16th largest position. Boxer Capital LLC’s holdings in Strongbridge Biopharma PLC were worth $4,465,000 as of its most recent filing with the SEC.
A number of other institutional investors have also modified their holdings of SBBP. Broadfin Capital LLC boosted its position in shares of Strongbridge Biopharma PLC by 3.0% in the first quarter. Broadfin Capital LLC now owns 2,981,706 shares of the biotechnology company’s stock worth $14,163,000 after buying an additional 87,125 shares during the last quarter. Opaleye Management Inc. acquired a new position in shares of Strongbridge Biopharma PLC during the fourth quarter worth approximately $2,784,000. Finally, Vivo Capital LLC acquired a new position in shares of Strongbridge Biopharma PLC during the fourth quarter worth approximately $7,200,000.
Shares of Strongbridge Biopharma PLC (NASDAQ:SBBP) traded down 3.49% during midday trading on Friday, reaching $4.15. 37,494 shares of the company’s stock were exchanged. Strongbridge Biopharma PLC has a 12-month low of $2.00 and a 12-month high of $6.24. The stock’s market cap is $146.64 million. The stock’s 50 day moving average is $4.47 and its 200-day moving average is $3.62.
Strongbridge Biopharma PLC (NASDAQ:SBBP) last announced its earnings results on Tuesday, May 16th. The biotechnology company reported ($0.33) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.16. On average, equities analysts expect that Strongbridge Biopharma PLC will post ($2.06) EPS for the current year.
TRADEMARK VIOLATION WARNING: “Boxer Capital LLC Continues to Hold Position in Strongbridge Biopharma PLC (SBBP)” was originally posted by sleekmoney and is owned by of sleekmoney. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://sleekmoney.com/boxer-capital-llc-continues-to-hold-position-in-strongbridge-biopharma-plc-sbbp/1916380.html.
A number of equities analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating on shares of Strongbridge Biopharma PLC in a research report on Wednesday, May 17th. Zacks Investment Research lowered shares of Strongbridge Biopharma PLC from a “hold” rating to a “sell” rating in a report on Wednesday, May 17th.
Strongbridge Biopharma PLC Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Want to see what other hedge funds are holding SBBP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Strongbridge Biopharma PLC (NASDAQ:SBBP).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/boxer-capital-llc-continues-to-hold-position-in-strongbridge-biopharma-plc-sbbp/1916380.html
Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.